Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: A 3-year follow-up study

Jack R. Cornelius, Duncan B. Clark, Oscar G. Bukstein, Thomas M. Kelly, Ihsan M Salloum, D. Scott Wood

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The goal of this 3-year follow-up evaluation was to determine whether the decreases in drinking and in depressive symptoms that were noted during our acute phase study with fluoxetine in comorbid adolescents persisted at a 3-year follow-up evaluation. At the 3-year follow-up evaluation, the group continued to demonstrate significantly fewer DSM criteria for an AUD and fewer BDI depressive symptoms and also consumed fewer standard drinks than they had demonstrated at the baseline of the acute phase study. However, 7 of the 10 participants demonstrated MDD at the 3-year follow-up assessment, and 4 demonstrated an AUD. The presence of a MDD was significantly correlated with the presence of an AUD at both the 1-year and the 3-year follow-up assessments. Four of the participants restarted SSRI medications during the follow-up period. Half of the subjects graduated from college during the 3-year assessment period, despite their residual depressive symptoms and drinking. We conclude that the long-term therapeutic effects of an acute phase trial of fluoxetine plus psychotherapy slowly decrease but did not disappear when fluoxetine is discontinued shortly after the acute phase trial. The high rate of MDD at follow-up suggests that longer term antidepressant medication treatment may be needed for at least some comorbid adolescents.

Original languageEnglish
Pages (from-to)807-814
Number of pages8
JournalAddictive Behaviors
Volume26
Issue number4
DOIs
StatePublished - Dec 1 2001
Externally publishedYes

Fingerprint

Fluoxetine
Alcohols
Depression
Drinking
Therapeutic Uses
Psychotherapy
Antidepressive Agents
Therapeutics

Keywords

  • Adolescents
  • Alcohol use disorder
  • Fluoxetine
  • Follow-up
  • Major depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder : A 3-year follow-up study. / Cornelius, Jack R.; Clark, Duncan B.; Bukstein, Oscar G.; Kelly, Thomas M.; Salloum, Ihsan M; Wood, D. Scott.

In: Addictive Behaviors, Vol. 26, No. 4, 01.12.2001, p. 807-814.

Research output: Contribution to journalArticle

Cornelius, Jack R. ; Clark, Duncan B. ; Bukstein, Oscar G. ; Kelly, Thomas M. ; Salloum, Ihsan M ; Wood, D. Scott. / Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder : A 3-year follow-up study. In: Addictive Behaviors. 2001 ; Vol. 26, No. 4. pp. 807-814.
@article{d2de60c422ef44e2aeda1cafd536590b,
title = "Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: A 3-year follow-up study",
abstract = "The goal of this 3-year follow-up evaluation was to determine whether the decreases in drinking and in depressive symptoms that were noted during our acute phase study with fluoxetine in comorbid adolescents persisted at a 3-year follow-up evaluation. At the 3-year follow-up evaluation, the group continued to demonstrate significantly fewer DSM criteria for an AUD and fewer BDI depressive symptoms and also consumed fewer standard drinks than they had demonstrated at the baseline of the acute phase study. However, 7 of the 10 participants demonstrated MDD at the 3-year follow-up assessment, and 4 demonstrated an AUD. The presence of a MDD was significantly correlated with the presence of an AUD at both the 1-year and the 3-year follow-up assessments. Four of the participants restarted SSRI medications during the follow-up period. Half of the subjects graduated from college during the 3-year assessment period, despite their residual depressive symptoms and drinking. We conclude that the long-term therapeutic effects of an acute phase trial of fluoxetine plus psychotherapy slowly decrease but did not disappear when fluoxetine is discontinued shortly after the acute phase trial. The high rate of MDD at follow-up suggests that longer term antidepressant medication treatment may be needed for at least some comorbid adolescents.",
keywords = "Adolescents, Alcohol use disorder, Fluoxetine, Follow-up, Major depression",
author = "Cornelius, {Jack R.} and Clark, {Duncan B.} and Bukstein, {Oscar G.} and Kelly, {Thomas M.} and Salloum, {Ihsan M} and Wood, {D. Scott}",
year = "2001",
month = "12",
day = "1",
doi = "10.1016/j.addbeh.2004.08.025",
language = "English",
volume = "26",
pages = "807--814",
journal = "Addictive Behaviors",
issn = "0306-4603",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder

T2 - A 3-year follow-up study

AU - Cornelius, Jack R.

AU - Clark, Duncan B.

AU - Bukstein, Oscar G.

AU - Kelly, Thomas M.

AU - Salloum, Ihsan M

AU - Wood, D. Scott

PY - 2001/12/1

Y1 - 2001/12/1

N2 - The goal of this 3-year follow-up evaluation was to determine whether the decreases in drinking and in depressive symptoms that were noted during our acute phase study with fluoxetine in comorbid adolescents persisted at a 3-year follow-up evaluation. At the 3-year follow-up evaluation, the group continued to demonstrate significantly fewer DSM criteria for an AUD and fewer BDI depressive symptoms and also consumed fewer standard drinks than they had demonstrated at the baseline of the acute phase study. However, 7 of the 10 participants demonstrated MDD at the 3-year follow-up assessment, and 4 demonstrated an AUD. The presence of a MDD was significantly correlated with the presence of an AUD at both the 1-year and the 3-year follow-up assessments. Four of the participants restarted SSRI medications during the follow-up period. Half of the subjects graduated from college during the 3-year assessment period, despite their residual depressive symptoms and drinking. We conclude that the long-term therapeutic effects of an acute phase trial of fluoxetine plus psychotherapy slowly decrease but did not disappear when fluoxetine is discontinued shortly after the acute phase trial. The high rate of MDD at follow-up suggests that longer term antidepressant medication treatment may be needed for at least some comorbid adolescents.

AB - The goal of this 3-year follow-up evaluation was to determine whether the decreases in drinking and in depressive symptoms that were noted during our acute phase study with fluoxetine in comorbid adolescents persisted at a 3-year follow-up evaluation. At the 3-year follow-up evaluation, the group continued to demonstrate significantly fewer DSM criteria for an AUD and fewer BDI depressive symptoms and also consumed fewer standard drinks than they had demonstrated at the baseline of the acute phase study. However, 7 of the 10 participants demonstrated MDD at the 3-year follow-up assessment, and 4 demonstrated an AUD. The presence of a MDD was significantly correlated with the presence of an AUD at both the 1-year and the 3-year follow-up assessments. Four of the participants restarted SSRI medications during the follow-up period. Half of the subjects graduated from college during the 3-year assessment period, despite their residual depressive symptoms and drinking. We conclude that the long-term therapeutic effects of an acute phase trial of fluoxetine plus psychotherapy slowly decrease but did not disappear when fluoxetine is discontinued shortly after the acute phase trial. The high rate of MDD at follow-up suggests that longer term antidepressant medication treatment may be needed for at least some comorbid adolescents.

KW - Adolescents

KW - Alcohol use disorder

KW - Fluoxetine

KW - Follow-up

KW - Major depression

UR - http://www.scopus.com/inward/record.url?scp=22444445897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22444445897&partnerID=8YFLogxK

U2 - 10.1016/j.addbeh.2004.08.025

DO - 10.1016/j.addbeh.2004.08.025

M3 - Article

C2 - 15833583

AN - SCOPUS:22444445897

VL - 26

SP - 807

EP - 814

JO - Addictive Behaviors

JF - Addictive Behaviors

SN - 0306-4603

IS - 4

ER -